Recent developments in the field of breast cancer

1. Optimization of treatment programmes: On the basis of an autonomous “multigen model” developed by the research team at the Oncology Hospital of the University of Jordan, the precision treatment of triple-negative breast cancer through the Zen Circa Vigura programme, which runs along the lines of the joint “Ghisitabin” Kappa, has significantly increased the survival rate of high-risk patients by more than 10 per cent and has changed the situation of traditional triple-negative breast cancer support therapy, the “thousands of people”. This research was published in the British Journal of Medicine in October 2024. • Endocrine co-treatment to overcome drug resistance: a study by Prof. Jiang Zephyi of the Fifth Medical Centre of the General Hospital of the People’s Liberation Army of China found that the selective group deacete acetamide (HDAC) inhibitor Sidapentamine co-endocrine treatment could significantly improve the survival benefits of HR positive and HeR2 late-negative breast cancer patients who had received endocrine treatment after recurrence or progress. 2. Development and application of new drugs: CDK4/6 inhibitors offer new hope: CDK4/6 inhibitors, such as Riposili, can enhance the effectiveness of endocrine treatment, significantly improve endocrine treatment resistance, reduce the risk of re-emergence and death by about 25 per cent, apply to early, medium and late breast cancer patients, and modify the treatment patterns for late breast cancer patients. In the NCCN Guide, version 3 of 2024, HR+/HER2- was the first-line treatment for late-stage breast cancer, and Riposili was recommended as a category 1 for both UAI and fluoride. • Development of Anti-Vioc Drug (ADC): The ADC drug provides new tools for the treatment of breast cancer by being able to direct the delivery of powerful chemotherapy to breast cancer cells. For example, drugs such as T-DXD show some efficacy in the treatment of low-expression breast cancer in Her2. 3. Advances in vaccine research: • Vaccine prevention: There is a three-stage alpha-protein vaccine for patients with a genetic mutation of BRCA1 and BRCA2. These genetic mutations increase the risk of breast cancer and the development of vaccines is expected to provide preventive measures for high-risk populations. • Vaccine treatment: The treatment vaccine for Her2-positive patients is also in three clinical stages and may in the future provide individualized treatment options depending on the situation of breast cancer patients. 4. Innovations in treatment technology: • Partial intervention + embolism treatment: For some breast cancer patients who are terminally inoperable, local intervention + embolism treatment is a new attempt. New treatments for late-stage breast cancer are provided through the delivery of high-concentration drugs directly to the oncology area through carrying microballs. 5. Upgrading of diagnostic techniques: • Multigenetic testing: multigenetic testing techniques allow for a more accurate assessment of breast cancer risks, prognosis and response to treatment, and help doctors develop more personalized treatment programmes. For example, detection of genetic expression levels associated with breast cancer determines whether the patient is fit for specific target or immunotherapy treatment. • Artificial intelligence-assisted diagnosis: Artificial intelligence technology plays an increasingly important role in the diagnosis of breast cancer. Through the analysis and learning of a large amount of mammogram data, artificial intelligence can help doctors to identify breast cancer more accurately and improve the accuracy and efficiency of diagnosis.